source
- CBER Director Karim Mikhail Aims to Restore Stability After Turbulent Leadership ChangesThe FDA's Center for Biologics Evaluation and Research (CBER) is working to regain stability after a period of rapid leadership turnover. Karim Mikhail, who was confirmed as the permanent director…
- AI startup Chai Discovery inks GSK deal to develop biologics using artificial intelligenceChai Discovery, an artificial‑intelligence focused biotech, has signed a collaboration agreement with GlaxoSmithKline to create biologic medicines using its AI platform. The partnership will lever…